GLUCOTRACK ANNOUNCES INCREASED SENSOR LONGEVITY FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

Stock Information for Integrity Applications

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Integrity Applications

Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements
Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights
Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering
GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR
Glucotrack, Inc. Announces Closing of $10.0 Million Public Offering and Concurrent Private Placement Converting $4.0 in Outstanding Debt
Glucotrack, Inc. Announces Pricing of $10.0 Million Public Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.